DEBRA Research and Dermaliq Therapeutics collaborate to advance treatment for rare skin disorder
Ella Day | May 29, 2025 | News story | Research and Development | DEBRA Research, Dermaliq Therapeutics, Dermatology, epidermolysis bullosa, non-profit organisation, skin disorders
Global non-profit organisation, DEBRA Research, and clinical dermatology company, Dermaliq Therapeutics, have announced a collaboration to advance drug development for those affected by epidermolysis bullosa (EB). EB is a group of rare, genetic skin disorders with no known cure, meaning new treatments are a highly pressing medical need.
The partners will initially focus on improving wound-healing and anti-itch therapies, alongside developing prophylactic therapies for patients. Under the agreement, DEBRA Research has also made a strategic investment in Dermaliq.
EB is characterised by extremely fragile skin, leading to blisters and wounds from even minor friction or trauma. It significantly compromises patients’ quality of life (QoL) and is associated with substantial morbidity and mortality. Current treatments focus on managing symptoms, reducing pain and improving QoL.
Using its hyliQ technology, Dermaliq is developing therapies that allow for active compounds to be delivered into the skin without mechanical interference to fragile tissue, allowing preservation of the integrity of compromised skin.
“We are excited to join forces with DEBRA Research to bring our technology to an area of urgent and unmet medical need,” said Frank Löscher, CEO of Dermaliq.
Christoph Coch, managing director at DEBRA Research, commented: “This collaboration will play a pivotal role in advancing transformative therapies and improving both medical outcomes and QoL for those affected by this devastating condition.”
Ella Day
29/5/25
Related Content
Promising interim Phase 3 data spurs epidermolysis bullosa trial expansion for Amryt
Rare disease firm Amryt has announced interim efficacy data for its epidermolysis bullosa (EB) therapy …
Amicus pulls plug on rare skin disease drug after Phase 3 failure
New Jersey-based biotech firm Amicus Therapeutics has been forced to terminate its development of its …
